Passage BIO, Inc.
No SEC Form 4 filings for $PASG in the last 30 days.
See all $PASG insider activity →Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”), Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the
Passage Bio, Inc. (PASG) reported a quarter ended 2026 with comprehensive loss and net loss of $7.82M, compared with $9.39M a year earlier, and diluted loss per share of $2.44 versus $2.96. The company said it signed a merger agreement with Remix, expects closing in Q4 2026 with $100M financing, is winding down AAV programs, and has $24.2M cash as of June 30, 2026.
Lynx1 Capital Management LP purchased 50,055 indirectly-held shares of Passage BIO, Inc. (PASG) at $4.12 ($0.21M total) on 2026-06-25.
Over the past 7 days, alphai's AI scored 1 news story mentioning PASG (Passage BIO, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PASG coverage spans financial news, corporate actions and insider activity.
The amendment restructures the two‑step merger and adds pre‑funded warrants, potentially diluting existing shareholders but securing financing.
The filing combines worsening quarterly losses with multiple execution risks (gene-therapy wind-down, restructuring progress, and merger closing/liquidity dependence).
A 10% owner’s open-market indirect purchase is a modest, sentiment-oriented signal but not a fundamental catalyst by itself.
Deal announcement via 8-K increases takeover/merger probability and sets up near-term catalysts (proxy/stockholder vote, regulatory approvals, closing conditions).
Oppenheimer's initiation of coverage with an outperform rating and a $30 target suggests strong upside potential for Passage Bio, driven by undervaluation after a 46% decline this year.
alphai scores every news story that mentions PASG with an AI model for sentiment and relevance, and aggregates insider trades from Passage BIO, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”), Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the
2 min readPassage Bio, Inc. (PASG) reported a quarter ended 2026 with comprehensive loss and net loss of $7.82M, compared with $9.39M a year earlier, and diluted loss per share of $2.44 versus $2.96. The company said it signed a merger agreement with Remix, expects closing in Q4 2026 with $100M financing, is winding down AAV programs, and has $24.2M cash as of June 30, 2026.
1 min readLynx1 Capital Management LP purchased 50,055 indirectly-held shares of Passage BIO, Inc. (PASG) at $4.12 ($0.21M total) on 2026-06-25.
2 min readPassage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2618476d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: PASSAGE BIO, INC.; PEREGRINE MERGER SUB, INC.; and REMIX THERAPEUTICS, INC. Dated as of June 24, 2026 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATIVE PROVISIONS 3 1.1
4 min readOppenheimer has initiated coverage of Passage Bio Inc. (NASDAQ:PASG) with an outperform rating and a price target of $30.00, suggesting a significant upside of 385% from its current price. The firm believes the stock's 46% year-to-date decline is an overreaction to competitor program failures and regulatory concerns, presenting a buying opportunity. Oppenheimer highlighted key differentiators for Passage Bio's lead asset PBFT02 in frontotemporal dementia, projecting $1 billion in peak risk-adjusted sales by 2040.
3 min readActively enrolling Cohort 3 ( FTD-GRN ) and Cohort 4 ( FTD-C9orf72 ) patients in ongoing upliFT-D study ...
3 min readThe mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 min readPHILADELPHIA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. PASG, a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C.
3 min readPHILADELPHIA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. ( NASDAQ: PASG ) , a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C.
2 min readThe mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 min read
